TransMedics Group, Inc. (TMDX) saw its stock price surge 6.07% in pre-market trading on Friday, following the company's impressive fourth-quarter 2024 financial results and a robust outlook for 2025.

The medical technology company reported better-than-expected earnings and revenue for the fourth quarter. Earnings per share came in at $0.19, beating analysts' estimates of $0.18 by a modest margin. Revenue rose 49.83% year-over-year to $121.62 million, surpassing the consensus estimate of $110.29 million by a significant margin.

TransMedics Group's strong performance was driven by robust demand for its products and services, as well as operational efficiency and profitability, highlighted by a gross margin of 59% and positive income from operations and net income. Adding to the positive sentiment, TransMedics Group provided an upbeat revenue outlook for 2025. The company expects full-year revenue to range between $530 million and $552 million, exceeding the consensus estimate of $521.62 million. This guidance reflects the company's confidence in its growth prospects and the continued adoption of its innovative solutions.